Enteris BioPharma, which was formed in August 2013, will offer contract manufacturing with the investment of up to $1 million into its 32,000-square-foot, FDA-approved manufacturing plant. The upgrades will allow it to make active pharmaceutical ingredients (APIs) up to commercial scale using microbial expression systems. Enteris got its start after buying the Peptelligence platform, a nasal delivery technology and the recombinant manufacturing process from Unigene Laboratories when that company ran into financial difficulties. "With the initiation of our contract manufacturing services, Enteris offers pharmaceutical partners the ability to manufacture recombinant peptide and protein products using microbial expression systems in an FDA inspected and cGMP compliant facility located in New Jersey," Enteris Vice President of Operations Paul Shields said in today's announcement. Release